Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Rhea-AI Summary

Ardelyx (Nasdaq: ARDX) management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 4:30 pm GMT / 11:30 am ET. Investors can watch a live webcast via the Events and Presentations page on the Ardelyx website. A replay will be available on the Ardelyx website for 30 days after the event.

The presentation offers a chance to hear management commentary and corporate updates directly; access is through the company website's investor events page.

News Market Reaction – ARDX

+6.25%

1 alert

+6.25% News Effect

On the day this news was published, ARDX gained 6.25%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 4:30 pm GMT/11:30 am ET.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ardelyx.com/. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the event.

About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. The company is developing RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

When will Ardelyx (ARDX) present at the Jefferies Global Healthcare Conference in London?

Ardelyx will present on Wednesday, November 19, 2025 at 4:30 pm GMT / 11:30 am ET.

How can investors watch the Ardelyx (ARDX) fireside chat webcast on November 19, 2025?

Watch the live webcast on the Events and Presentations page of the Ardelyx website at https://ardelyx.com/.

Will a replay of the Ardelyx (ARDX) Jefferies conference presentation be available?

Yes. A replay will be available on the Ardelyx website for 30 days following the event.

What time is the Ardelyx (ARDX) presentation for US investors on November 19, 2025?

The presentation begins at 11:30 am ET for US investors.

What topics will Ardelyx (ARDX) management cover at the Jefferies Global Healthcare Conference?

Management will participate in a fireside chat to discuss recent developments and corporate outlook; specific topics were not detailed in the announcement.

Where can I find the Ardelyx (ARDX) webcast and replay after the Jefferies conference?

Both the live webcast and replay are posted on the Ardelyx website under Events and Presentations.